文献速递临床试验与 GCP

大缺血性卒中跨缺血损伤与半暗带特征的血管内取栓治疗

Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles.
PubMed 文献 · JAMA · 2024-01-01

SELECT2试验的探索性分析纳入336例大核心急性缺血性卒中患者,评估血管内取栓(EVT)与药物管理(MM)在不同缺血损伤程度下的疗效。结果显示,在ASPECTS 3、4、5分及核心体积≥70 mL时EVT改善功能结局,但核心体积≥100 mL和≥150 mL的95%CI跨1;EVT组缺血损伤越重结局越差。

要点

  • ASPECTS 3、4、5分患者中EVT较MM改善90天功能结局(aGenOR分别为1.71、2.01、1.85)。
  • 核心体积≥70 mL时EVT优于MM(aGenOR 1.63,95%CI 1.23-2.16)。
  • EVT组ASPECTS每降1分或核心体积每增10 mL,功能结局更差。

核心结论

  • 在广泛梗死体积的大缺血性卒中患者中,EVT改善了临床结局,但半暗带体积极小患者的入组人数较少。
  • 在接受EVT治疗的患者中,就诊时缺血损伤估计值越大,临床结局越差。

研究设计与样本

  • SELECT2试验的探索性分析,随机纳入352例18-85岁因颈内动脉或大脑中动脉M1段闭塞所致大缺血核心急性缺血性卒中成人患者,比较EVT与药物管理(MM)。
  • 研究在2019年10月至2022年9月期间于31个全球中心开展。
  • 共336例患者纳入分析(中位年龄67岁;139例[41.4%]女性),其中168例(50%)随机分配至EVT,另有2例交叉的MM患者接受了EVT。

主要发现

  • 90天mRS序贯分析显示,EVT较MM改善功能结局:ASPECTS 3分aGenOR 1.71(95%CI 1.04-2.81),4分aGenOR 2.01(95%CI 1.19-3.40),5分aGenOR 1.85(95%CI 1.22-2.79)。
  • 按CT灌注/MRI缺血核心体积分层,EVT vs MM的aGenOR在≥70 mL为1.63(95%CI 1.23-2.16),≥100 mL为1.41(95%CI 0.99-2.02),≥150 mL为1.47(95%CI 0.84-2.56)。
  • EVT组中,ASPECTS每降低1分功能结局恶化(aGenOR 0.91,95%CI 0.82-1.00),CT灌注/MRI缺血核心体积每增加10 mL功能结局恶化(aGenOR 0.92,95%CI 0.89-0.95)。
  • 无论是否存在不匹配,均未观察到EVT治疗效应的异质性,但无不匹配的患者入组较少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 半暗带体积极小患者的入组人数较少。
  • 原文报告为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether endovascular thrombectomy (EVT) efficacy for patients with acute ischemic stroke and large cores varies depending on the extent of ischemic injury is uncertain. OBJECTIVE: To describe the relationship between imaging estimates of irreversibly injured brain (core) and at-risk regions (mismatch) and clinical outcomes and EVT treatment effect. DESIGN, SETTING, AND PARTICIPANTS: An exploratory analysis of the SELECT2 trial, which randomized 352 adults (18-85 years) with acute ischemic stroke due to occlusion of the internal carotid or middle cerebral artery (M1 segment) and large ischemic core to EVT vs medical management (MM), across 31 global centers between October 2019 and September 2022. INTERVENTION: EVT vs MM. MAIN OUTCOMES AND MEASURES: Primary outcome was functional outcome-90-day mRS score (0, no symptoms, to 6, death) assessed by adjusted generalized OR (aGenOR; values >1 represent more favorable outcomes). Benefit of EVT vs MM was assessed across levels of ischemic injury defined by noncontrast CT using ASPECTS score and by the volume of brain with severely reduced blood flow on CT perfusion or restricted diffusion on MRI. RESULTS: Among 352 patients randomized, 336 were analyzed (median age, 67 years; 139 [41.4%] female); of these, 168 (50%) were randomized to EVT, and 2 additional crossover MM patients received EVT. In an ordinal analysis of mRS at 90 days, EVT improved functional outcomes compared with MM within ASPECTS categories of 3 (aGenOR, 1.71 [95% CI, 1.04-2.81]), 4 (aGenOR, 2.01 [95% CI, 1.19-3.40]), and 5 (aGenOR, 1.85 [95% CI, 1.22-2.79]). Across strata for CT perfusion/MRI ischemic core volumes, aGenOR for EVT vs MM was 1.63 (95% CI, 1.23-2.16) for volumes ≥70 mL, 1.41 (95% CI, 0.99-2.02) for ≥100 mL, and 1.47 (95% CI, 0.84-2.56) for ≥150 mL. In the EVT group, outcomes worsened as ASPECTS decreased (aGenOR, 0.91 [95% CI, 0.82-1.00] per 1-point decrease) and as CT perfusion/MRI ischemic core volume increased (aGenOR, 0.92 [95% CI, 0.89-0.95] per 10-mL increase). No heterogeneity of EVT treatment effect was observed with or without mismatch, although few patients without mismatch were enrolled. CONCLUSION AND RELEVANCE: In this exploratory analysis of a randomized clinical trial of patients with extensive ischemic stroke, EVT improved clinical outcomes across a wide spectrum of infarct volumes, although enrollment of patients with minimal penumbra volume was low. In EVT-treated patients, clinical outcomes worsened as presenting ischemic injury estimates increased. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03876457.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sarraj A, Hassan AE, Abraham MG, et al. Endovascular Thrombectomy for Large Ischemic Stroke Across Ischemic Injury and Penumbra Profiles. JAMA. 2024. PMID: 38324414. doi:10.1001/jama.2024.0572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。